Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBD1016 in chronic hepatitis B
NCT05961098Phase 2Completed
- Sponsor
- Suzhou Ribo Life Science Co., Ltd.
- Start
- Oct 2023
- Primary completion
- Apr 2025
- Modality
- Conjugated siRNA, Small Molecules, Chemically Modified siRNA
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of RBD1016 in Chronic Hepatitis B (CHB) (3 arms), sponsored by Suzhou Ribo Life Science Co., Ltd. Primary endpoints: Adverse Events at 24 weeks and Maximum decline of HBsAg at 24 weeks. Started Oct 2023; status: completed.
02
Drugs
RBD1016
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05961098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05961098.